Merdury

Mercury Therapeutics is a biotechnology company focused on the discovery and development of small molecule drugs that target AMP-activated protein kinase (AMPK), a master regulator of energy metabolism. By developing potent and selective AMPK activators and inhibitors, the company aims to treat a wide range of metabolic diseases, including type 2 diabetes and obesity, as well as various forms of cancer. Their proprietary platform enables the identification of isoform-specific modulators to optimize therapeutic efficacy while minimizing off-target effects. Mercury Therapeutics leverages its deep expertise in metabolic signaling to advance a pipeline of novel candidates through early-stage research and pre-clinical development.